利伐沙班与低分子肝素对老年糖尿病患者全髋关节置换术后深静脉血栓预防的对比研究

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (42 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the prevention role of rivaroxaban and low molecular weight heparin in elderly diabetes patients with deep vein thrombosis after total hip replacement.Methods 72 patients who conducted total hip replacement underwent elective were selected from May 2014 to August 2015 of our hospital and diagnosed as diabetic from medical department.Patients were randomly divided into group A（rivaroxaban group，n=36）and group B（low molecular weight heparin group，n=36）according to random number table.Patients in group A were given oral administration rivaroxaban 10 h after operation and 10 mg once a day.Patients in group B were given hypodermic injection low molecular weight heparin 10 h after operation with the dose of 4100 IU.Both lower extremities deep veins color doppler ultrasound were conducted both before and after operation to record the incidence rate of deep venous thrombosis and postoperative bleeding.The coagulation markers that before operation and 2 days，7 days and 14 days after operation and fasting blood-glucose value were tested.Results The deep venous thrombosis rate in group A　（2.8%）was lower than that of group B（4.6%），and the difference had no statistical significance（P＞0.05）；the value of D-dimer increased obvious at 2 days and 7 days after operation in both two groups，and the difference was statistical significance（P＜0.05）；the value of D-dimer increased at 7 days and 14 days descended than at 2 days，and the difference was statistical significance（P＜0.05）；compared the D-dimer at 14 days between two group，the difference was statistical significance　（P＜0.05）and the decline scope of D-dimer in group A was more than that of group B；the postoperative bleeding in both two groups had no statistical significance（P＞0.05）；the fasting blood-glucose at all times in two groups had no statistical significance （P＞0.05）.Conclusion Both rivaroxaban and low molecular weight heparin have role in preventing elderly diabetes patients with deep vein thrombosis after total hip replacement.The role of rivaroxaban is better than low molecular weight heparin，there is no obvious increase bleeding and has little effect on blood-glucose.

Key words： Rivaroxaban Low molecular weight heparin Total hip replacement Deep vein thrombosis Diabetic

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAO Yin-li
	GAO Dong-yan
	ZHANG Zhi-qiang
	SHI Jin-xiu

Cite this article:

HAO Yin-li,GAO Dong-yan,ZHANG Zhi-qiang, et al. Comparing the prevention role of rivaroxaban and low molecular weight heparin in elderly diabetes patients with deep vein thrombosis after total hip replacement[J]. 中国当代医药, 2016, 23(10): 141-143转146.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I10/141

［1］	王斌，元占玺.关节置换术后深静脉血栓相关危险因素及预防研究进展［J］.中国实用医刊，2013，40（14）：118-120.
［2］	田华，宋飞，张克，等.阿司匹林预防关节置换术后血栓栓塞性疾病的疗效和安全性研究［J］.中华医学杂志，2007，87（47）：3349-3352.
［3］	陆慧杰，庄汝杰，陈之青.利伐沙班对比依诺肝素预防骨科大手术后深静脉血栓形成的疗效与安全性评价［J］.中国临床药理学杂志，2015，31（9）：693-695.
［5］	吴星，高书图，刘又文.利伐沙班预防全髋关节置换术后深静脉血栓形成的临床观察［J］.风湿病与关节炎，2015，4（8）：21-23.
［7］	陶树贵.益气活血方在预防下肢骨折术后深静脉血栓形成的临床疗效［J］.湖南中医药大学学报，2013，33（10）：33-34.
［8］	于华齐，周春晖.利伐沙班与依诺肝素对人工全髋关节置换术后深静脉血栓预防的临床效果和安全性分析［J］.山西医药杂志，2013，42（3）：311-313.
［4］	Brandao GM，Sobreira ML，Malgor RD，et al.Recanalization rates after acute deep vein thrombosis：a single-center experience using a newly proposed vein diameter variation index［J］.Ann Vasc Surg，2014，28（7）：1751-1760.
［6］	Eriksson BI，Rosencher N，Friedman RJ，et al.Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty［J］.Thromb Res，2012，130（2）：147-151.
［9］	杜伟，刘建青，赵春红.利伐沙班、低分子肝素钠、间歇性充气加压装置预防腰椎手术后静脉血栓栓塞的比较［J］.中华临床医师杂志，2013，17（3）：1049-1054.
［10］	Ufer M.Comparative efficacy and safety of the novel oral anticoagulants dabigatran，rivaroxaban and apixaban in preclinical and clinical development［J］.Thromb Haemost，2010，103（3）：572-585.
［11］	Eriksson BI，Dahl OE，Rosencher N，et al.Oral dabigatran etexilate vs.subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement：the RE-MODEL randomized trial［J］.J Thromb Haemost，2007，5（11）：2178-2185.
［12］	Eriksson BI，Borris LC，Friedman RJ，et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty［J］.N Engl J Med，2008，358（26）：2765-2775.
［13］	Eriksson BI，Dahl OE，Huo MH，et al.Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty（RE-NOVATEⅡ*）.A randomised，double-blind，non-inferiority trial［J］.Thromb Haemost，2011，105（4）：721-729.
［14］	LereunC，WellsP，DiamantopoulosA，etal.Anindirectcomparison，via enoxaparin of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement［J］.J Med Econ，2011，14（2）：238-244.
［15］	余世明，张阳春.糖尿病患者行髋关节置换73例［J］.中国组织工程研究与临床康复，2011，15（43）：8163-8167.
［16］	zler T，Ulucay，nal A，et al.Comparison of switch-therapy modalities（enoxaparin to rivaroxaban/dabigatran）and enoxaparin monotherapy after hip and knee replacement ［J］.Acta Orthop Turc，2015，49（3）：255-259.
［17］	Geers WH，Bergqvist D，Pineo.GF，et al.Prevention of venous thromboembolism：American college of chest physician evidence based clinical practice guidelines（8th edition）［J］.Chest，2008，133（6 Suppl）：381S-453S.
［18］	吴歌，李贵斌，戴彬.利伐沙班与低分子肝素钙预防髋部骨折术后下肢深静脉血栓形成的有效性与安全性［J］.中国临床研究，2013，26（1）：5-7.
［19］	李竹岩.利伐沙班在人工关节置换术后深静脉血栓预防中的药理分析与临床应用研究［J］.中国实用医药，2015，10（25）：6-8.